24/7 Market News Snapshot 01 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)

August 1, 2025

DENVER, Colo., 01 August, 2025 (www.247marketnews.com) – (NASDAQ:BTAI) are discussed in this article.
BioXcel Therapeutics, Inc. (BTAI) is experiencing a significant surge in investor interest, with its stock trading at $1.631 in pre-market sessions, reflecting an impressive 24.50% increase from the prior day’s closing price of $1.310. This uptick is accompanied by a robust trading volume of 5.05 million shares, highlighting a growing enthusiasm for the company’s prospects within the biopharmaceutical sector. Such enthusiasm comes on the heels of positive developments, particularly in relation to the company’s SERENITY At-Home clinical trial.

The SERENITY At-Home trial, which recently concluded its last patient visit, is a pivotal Phase 3 study focusing on the safety of BXCL501, an oral dissolving film formulation of dexmedetomidine. This trial involved more than 200 patients across 22 clinical sites and gathered safety data from over 2,200 recorded episodes of agitation over 12 weeks. Topline results are expected in the coming weeks and are anticipated to support a supplemental New Drug Application (sNDA) aimed at expanding the approval of IGALMI® (dexmedetomidine) for outpatient use.

Dr. Vimal Mehta, CEO of BioXcel Therapeutics, expressed pride in the collaborative efforts that led to the study’s completion, emphasizing the significance of this milestone in offering innovative treatment solutions for individuals experiencing agitation due to bipolar disorder or schizophrenia. The need for effective treatments is pressing, given that approximately 23 million agitation episodes occur annually in domestic settings, with no FDA-approved medications currently available for acute treatment in such contexts.

The forthcoming data from the SERENITY trial is poised to enhance BioXcel’s position in the neuroscience field and reaffirm its commitment to delivering viable options for patients facing challenging psychiatric conditions, further solidifying its role as a leader in the industry. As market anticipation builds, BTAI’s trajectory is one to watch closely as it opens for trading.

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.